DMARD Therapy Research Articles

THU0069 Ultrasound-Guided Assessement of Axillary Lymph Node Reactivity/Structural Heterogeneity in Rheumatoid Arthritis: Relationship with Disease Activity and Joint Inflammation

BackgroundThere is growing evidence in the murine system suggesting that joint-draining lymph nodes (LN) and the afferent lymphatic system are relevant patho-phisiologic components of chronic arthritis acting through the control...

AB0188 Combination therapy with adalimumab plus methotrexate reduces circulating levels of pro-matrix matalloproteinases-1 and -3 independently of clinical disease activity in patients with rheumatoid arthritis

BackgroundIn patients (pts) with rheumatoid arthritis (RA), therapy with biologic agents such as adalimumab (ADA) can uncouple destruction of articular cartilage and bone from the inflammatory processes that drive clinical...

AB0503 A comparative study of early clinical efficacy among three anti-TNF agents – drag race study

BackgroundAnti-tumor necrosis factor (TNF) therapy is recommended when conventional DMARDs therapy fails to decrease disease activity of rheumatoid arthritis (RA) to at least low disease activity. One of the advantages...

THU0147 Predicting Eventual Need for Orthopaedic Surgery of Hand and Foot Joints. Value of Radiographic Scores in the First Three Years of RA in a Long Term Inception Cohort

BackgroundHand and foot surgery in Rheumatoid Arthritis (RA) is accepted as a surrogate marker for joint destruction and the result of failed medical treatment. The ability to predict this outcome...

SAT0280 Efficacy of Apremilast, An Oral Phosphodiesterase 4 Inhibitor, on Physical Function and Pain in Patients with Psoriatic Arthritis, Including Current Skin Involvement: Results of a Phase 3, Randomized, Controlled Trial

BackgroundApremilast (APR), an oral phosphodiesterase 4 inhibitor, works intracellularly to modulate inflammatory mediators.ObjectivesPALACE 3 compared APR vs placebo (PBO) in patients with active psoriatic arthritis (PsA) and 1 or more...

AB0573 Tocilizumab use in a diverse patient population: Single-centre tertiary experience

BackgroundTocilizumab is approved by the European Medicines Agency to treat rheumatoid arthritis (RA) and systemic-onset juvenile idiopathic arthritis (JIA).ObjectivesTo assess the efficacy and tolerability of tocilizumab in patients treated with...

OP0051 Joint damage progression in established rheumatoid arthritis: Common and strongly associated with seropositivity

BackgroundDuring the last decade, rheumatoid arthritis (RA) research has mainly focused on early disease, as it has become apparent that early and aggressive treatment can change the long-term outcome of...

FRI0074 Pre-clinical tooth loss at arthritis onset is associated with higher disease activity and worse treatment response in a large early arthritis cohort study

BackgroundGrowing evidence suggests an association between periodontitis (PD) with rheumatoid arthritis (RA). Chronic PD is a major cause of tooth loss and the number of teeth may therefore, to some...

SP0010 Long-term economic outcomes of modern treatment: Sick leave and work disability

Modern treatment for patients with chronic inflammatory joint diseases includes pharmacological as well as rehabilitation and joint surgery when needed. The major shift over the past decade in the pharmacological...

AB0584 Safety and efficacy of etanercept in patients with active psoriatic arthritis with peripheral involvement in belgium: 66 months follow-up.

Objectivesto describe the long-term efficacy and types of adverse events (AEs) in psoriatic arthritis (PsA) patients treated with etanercept in a daily clinical setting in Belgium.MethodsThis is a prospective, multi-center,...

THU0498 The Clinical Utility of the Accelerometer for Measuring Habitual Physical Activity in Patients with Rheumatoid Arthritis: A Longitudinal Study

BackgroundThere is growing interest in the use of patient reported outcomes in the assessment of rheumatoid arthritis (RA), along with standard clinical and physician assessments. Patients with RA are generally...

AB0410 Use of disease-modifying treatment (dmard) in patients with rheumatoid arthritis: clinical aspects

BackgroundRheumatoid arthritis (RA) is one of the most common occurrence diseases with a high frequency (about 1%) in the general population. More the 4500 patients with rheumatoid arthritis registered in...

SAT0048 Prevalence of Metabolic Syndrome in Patients with Rheumatoid Arthritis in Morocco: A Cross-Sectional Study of 179 Cases.

BackgroundRheumatoid arthritis (RA) is associated with increased morbidity and mortality due to cardiovascular disease. The metabolic syndrome (MetS) may contribute to the excess cardiovascular burden observed in RA. The prevalence...

FRI0100 Treat to target: defining the optimum target to prevent radiographic erosion progression during the first year of treatment in an early rheumatoid arthritis cohort

BackgroundThe target for most treat to target (T2T) regimes in early rheumatoid arthritis (eRA) is DAS28 remission. However, power Doppler ultrasound (PDUS) activity in patients in DAS28 remission is associated...

SAT0137 Early Clinical Improvements (Week 4) Predict Subsequent Clinical Response with Ixekizumab in Rheumatoid Arthritis Patients with Inadequate Response to tnf Inhibitors

BackgroundIxekizumab is an anti-IL-17 monoclonal antibody currently being investigated for treatment of rheumatoid arthritis (RA). Ixekizumab has previously been shown to reduce the signs and symptoms of RA in patients...

OP0104 Apremilast, an Oral Phosphodiesterase 4 Inhibitor, in Patients with Psoriatic Arthritis Including Current Skin Involvement: Results of a Phase 3, Randomized, Controlled Trial

BackgroundApremilast (APR), an oral phosphodiesterase 4 inhibitor, works intracellularly to modulate inflammatory mediators.ObjectivesPALACE 3 compared APR vs placebo (PBO) in patients with active psoriatic arthritis (PsA) and at least 1...

FRI0130 Change in disease outcomes after implementation of treat to target, including evaluation of power doppler ultrasound remission

BackgroundThe 2010 treatment to target guidelines recommend frequent assessment to achieve a pre-defined target (ideally remission) in early rheumatoid arthritis (RA) [1]. Power Doppler (PD) ultrasound has the ability to...

THU0224 Randomized Double-Blind Comparative Effectiveness in RA Patients with Active Disease Despite Methotrexate (MTX): A Comparison of Conventional Disease-Modifying Anti-Rheumatic Drugs with a Biological

BackgroundDouble-blind placebo controlled trials have demonstrated the efficacy of 16 different therapies in RA patients with active disease despite MTX. However, there have been no blinded trials comparing conventional combination...

AB0569 Effects of tocilizumab in combination with non biologic DMARDS on early improvement of anemia and fatigue in adult patients with moderate to severe active rheumatoid arthritis

BackgroundA significant number of RA patients (pts) have low haemoglobin (Hb) levels. Normalisation of Hb in anaemic RA pts may be a suitable marker of improvement in disease activity, as...

AB0542 Early reduction in synovitis and bone EDEMA evaluated by MRI in tocilizumab-treated RA patients with inadequate response to anti-TNF

ObjectivesTo evaluate early effects of tocilizumab (TCZ) on synovitis, bone edema and tenosynovitis by hand MRI in patients with active RA and inadequate response to anti-TNF.MethodsPatients with active RA (DAS28...